A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer

M. J. Barry, Jr Fowler, L. Bin, J. E. Oesterling, H. L. Holtgrewe

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Our aim was to define the spectrum of urological care for benign prostatic hyperplasia (BPH) and clinically localized prostate cancer. Materials and Methods: In 1995 a random sample of 394 American urologists was surveyed with a response rate of 67%. Results: Respondents reported seeing a median of 240 BPH patients during the preceding 12 months, and they had prescribed α-blockers for 70 and finasteride for 15. They had performed a median of 25 transurethral prostatectomies but few other operations for BPH. Almost all urologists routinely used digital rectal examinations and prostate specific antigen tests for BPH diagnosis. The next most common studies were American Urological Association symptom scores and uroflowmetry. Pressure- flow studies were rarely done. Respondents reported seeing a median of 35 new patients with prostate cancer during the last year, and performing a median of 90 prostate biopsies and 13 radical prostatectomies. Respondents had referred a median of 10 patients for external beam radiotherapy but few patients received brachytherapy or cryotherapy. Urologist staging practices varied considerably. Conclusions: These data provide a picture of current practice regarding the management of BPH and prostate cancer.

Original languageEnglish (US)
Pages (from-to)488-492
Number of pages5
JournalJournal of Urology
Volume158
Issue number2
DOIs
StatePublished - 1997
Externally publishedYes

Keywords

  • Physician's practice patterns
  • Practice guidelines
  • Prostate
  • Prostatic hypertrophy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer'. Together they form a unique fingerprint.

Cite this